中枢神経系バイオマーカーの世界市場レポート 2025年

中枢神経系バイオマーカーの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR10.0％で90億米ドルに成長します。予測期間の成長は、神経疾患の有病率の増加、個別化医療への需要の高まり、高齢者人口の増加、早期診断への注目の高まり、非侵襲的診断ツールへの需要の高まりに起因すると考えられます。予測期間の主な動向には、新技術の進歩、バイオテクノロジー企業、製薬企業、その他の利害関係者間の戦略的提携、脳脊髄液（csf）および血液ベースのバイオマーカーに関する研究の成長、AIおよび機械学習アルゴリズムの活用などが含まれます。

神経疾患の増加が予想されることから、中枢神経系バイオマーカー市場の今後の拡大が期待されます。神経疾患は神経障害とも呼ばれ、脳、脊髄、全身の神経に影響を及ぼす幅広い症状を包含します。これらの疾患は、遺伝的影響、感染症、自己免疫反応、退行過程、腫瘍、血管の問題、外傷性損傷など、さまざまな要因から生じる可能性があります。神経疾患の領域では、中枢神経系（CNS）バイオマーカーは、臨床診断、疾病リスクや予後の判定、病期の評価、治療反応のモニタリングにおいて重要な役割を果たしています。これらのバイオマーカーは、これらの疾患とその治療可能性の解明に大きく貢献しています。例えば、2023年4月、米国政府機関である疾病管理予防センターは、アルツハイマー病が65歳以上の米国人に推定670万人罹患していると報告し、2060年までにこの数が3倍の1,400万人になると予測しています。さらに、65歳以降は5年ごとに発症率が倍増するといいます。その結果、神経疾患の急増が中枢神経系バイオマーカー市場の成長を促進する主要因となっています。

肥満の有病率の増加は、今後数年間の中枢神経系バイオマーカー市場の拡大に拍車をかけると予想されます。肥満は、体脂肪の過剰によって特徴づけられる病状であり、個人の健康に悪影響を及ぼす可能性があります。中枢神経系バイオマーカーは肥満の研究に使用され、体重や食行動を制御する神経学的メカニズムの理解や、効果的な抗肥満治療の開発に役立っています。例えば、2023年3月、スイスに本部を置く世界の循環器系団体である世界心臓財団は、世界中で約23億人の大人と子供が肥満または過体重であると報告しました。現在の肥満動向では、2025年までに肥満の影響を受ける人の数は27億人に増加すると予測されています。このように、肥満の有病率の増加が中枢神経系バイオマーカー市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の中枢神経系バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の中枢神経系バイオマーカー市場：成長率分析
• 世界の中枢神経系バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の中枢神経系バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界の中枢神経系バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の中枢神経系バイオマーカー市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 安全性バイオマーカー
• 有効性バイオマーカー
• 検証バイオマーカー
• その他のタイプ
• 世界の中枢神経系バイオマーカー市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性硬化症
• アルツハイマー病
• パーキンソン病
• 外傷性脳損傷
• その他の疾患
• 世界の中枢神経系バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品の発見と開発
• パーソナライズ医療
• 疾病リスク評価
• 診断
• その他の用途
• 世界の中枢神経系バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断ラボ
• クリニック
• 病院
• 研究センター
• その他のエンドユーザー
• 世界の中枢神経系バイオマーカー市場、タイプ別サブセグメンテーション：安全性バイオマーカー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毒性バイオマーカー
• 有害事象バイオマーカー
• 世界の中枢神経系バイオマーカー市場、タイプ別サブセグメンテーション：有効性バイオマーカー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬力学的バイオマーカー
• レスポンスバイオマーカー
• 世界の中枢神経系バイオマーカー市場、タイプ別サブセグメンテーション：検証バイオマーカー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予測バイオマーカー
• 予後バイオマーカー
• 世界の中枢神経系バイオマーカー市場、タイプ別サブセグメンテーション：その他のタイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断バイオマーカー
• 病気の進行のバイオマーカー

第7章 地域別・国別分析

• 世界の中枢神経系バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の中枢神経系バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 中枢神経系バイオマーカー市場：競合情勢
• 中枢神経系バイオマーカー市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Eurofins Scientific
• Charles River Laboratories International Inc.
• PerkinElmer Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Axon Neuroscience SE
• Alector Inc.
• Oryzon Genomics S.A.
• Abastar Mdx Inc.
• Banyan Biomarkers Inc.
• Avacta Group PLC
• Geno Technology Inc.
• Anavex Life Sciences Corp.
• Alseres Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 中枢神経系バイオマーカー市場2029：新たな機会を提供する国
• 中枢神経系バイオマーカー市場2029：新たな機会を提供するセグメント
• 中枢神経系バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Central nervous system (CNS) biomarkers are specific substances or measurable indicators within the CNS that offer insights into normal functioning, disease processes, or responses to treatments. They play a crucial role in diagnosing or predicting neurological disorders, monitoring disease progression, and anticipating responses to drug therapy.

The primary categories of CNS biomarkers include safety biomarkers, efficacy biomarkers, validation biomarkers, and others. Safety biomarkers encompass measurable biological parameters or indicators employed to evaluate the safety of drugs, medical interventions, or environmental exposures. They find application in treating various diseases such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and more, contributing to drug discovery and development, personalized medicines, disease risk assessment, diagnostics, among other areas. Diverse end-users, such as diagnostic labs, clinics, hospitals, research centers, and others, utilize these biomarkers.

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides central nervous system biomarkers market statistics, including central nervous system biomarkers industry global market size, regional shares, competitors with a central nervous system biomarkers market share, detailed central nervous system biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. This central nervous system biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system biomarkers market size has grown rapidly in recent years. It will grow from $5.58 billion in 2024 to $6.15 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

The anticipated increase in neurological illnesses is expected to drive the expansion of the central nervous system biomarker market in the future. Neurological illnesses, also referred to as neurological disorders, encompass a broad spectrum of conditions affecting the brain, spinal cord, and nerves throughout the body. These disorders can result from various factors, including genetic influences, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In the realm of neurological disorders, central nervous system (CNS) biomarkers play a crucial role in clinical diagnosis, determining illness risk or prognosis, assessing disease stage, and monitoring treatment response. They contribute significantly to comprehending these diseases and their treatability. For instance, in April 2023, the Centers for Disease Control and Prevention, a US government agency, reported that Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older, with projections indicating a tripling of this number to 14 million by 2060. Furthermore, the incidence of the disease is observed to double every five years after the age of 65. Consequently, the surge in neurological illnesses is a key factor propelling the growth of the central nervous system biomarker market.

The growing prevalence of obesity is expected to fuel the expansion of the central nervous system biomarker market in the coming years. Obesity, a medical condition marked by an excess of body fat, can adversely affect an individual's health. Central nervous system biomarkers are employed to study obesity, aiding in the understanding of the neurological mechanisms that control body weight and eating behavior, as well as in the development of effective anti-obesity treatments. For example, in March 2023, the World Heart Foundation, a Switzerland-based global cardiovascular organization, reported that approximately 2.3 billion adults and children worldwide are either obese or overweight. With current obesity trends, it is projected that the number of people affected by obesity will rise to 2.7 billion by 2025. Thus, the increasing prevalence of obesity is driving the growth of the central nervous system biomarker market.

A prominent trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Leading companies in the market are dedicated to developing groundbreaking drugs and obtaining approvals to enhance their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, disclosed the approval and authorization of its investigational new drug (IND) application for DB104 (liafensine) by the US Food and Drug Administration (FDA) for treating treatment-resistant depression (TRD). This marks the initiation of the first biomarker-guided global CNS clinical trial for TRD. The drug has the potential to identify patients more likely to respond to liafensine, facilitating more personalized treatment decisions. Liafensine, a novel compound, functions by elevating levels of dopamine and norepinephrine in the brain.

Major players in the central nervous system biomarker market are strategically focused on introducing advanced solutions, such as assay kits. An assay kit is a pre-packaged set of reagents and materials utilized for a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a research and development company based in Japan, launched an Automated Immunoassay System. This assay kit is designed to detect amyloid beta (AB) accumulation in the brain, a contributor to Alzheimer's disease, using a small blood sample. The kit measures the ratio of AB peptides in the blood through an automated immunoassay system. This facilitates clinicians in identifying AB accumulation in the brain with a minimal blood sample, enabling earlier diagnosis and treatment for patients.

In June 2022, Fujirebio Holdings Inc., a biotechnology company based in Japan, acquired ADx NeuroSciences for approximately $43 million (40 million euros). This acquisition aims to broaden Fujirebio Holdings' portfolio of central nervous system biomarkers, leverage ADx NeuroSciences' expertise and technology, and enhance its global presence in the central nervous system biomarker market. ADx NeuroSciences, headquartered in Belgium, is a biomarker-assay company specializing in the development and production of biomarkers for central nervous system (CNS) disorders.

Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics

North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Safety Biomarker; Efficacy Biomarker; Validation Biomarker; Other Types
• 2) By Disease: Multiple Sclerosis; Alzheimer's Disease; Parkinson's Disease; Traumatic Brain Injury; Other Diseases
• 3) By Application: Drug Discovery And Development; Personalized Medicines; Disease Risk Assessment; Diagnostics; Other Applications
• 4) By End-Users: Diagnostic Labs; Clinics; Hospitals; Research Centers; Other End-Users
• Subsegments:
• 1) By Safety Biomarker: Toxicity Biomarkers; Adverse Event Biomarkers
• 2) By Efficacy Biomarker: Pharmacodynamic Biomarkers; Response Biomarkers
• 3) By Validation Biomarker: Predictive Biomarkers; Prognostic Biomarkers
• 4) By Other Types: Diagnostic Biomarkers; Biomarkers For Disease Progression
• Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Siemens Healthineers; Thermo Fisher Scientific Inc; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Central Nervous System Biomarkers Market Characteristics

3. Central Nervous System Biomarkers Market Trends And Strategies

4. Central Nervous System Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Central Nervous System Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Central Nervous System Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Central Nervous System Biomarkers Market Growth Rate Analysis
• 5.4. Global Central Nervous System Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Central Nervous System Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Central Nervous System Biomarkers Total Addressable Market (TAM)

6. Central Nervous System Biomarkers Market Segmentation

• 6.1. Global Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Safety Biomarker
• Efficacy Biomarker
• Validation Biomarker
• Other Types
• 6.2. Global Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Sclerosis
• Alzheimer's Disease
• Parkinson's Disease
• Traumatic Brain Injury
• Other Diseases
• 6.3. Global Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Discovery And Development
• Personalized Medicines
• Disease Risk Assessment
• Diagnostics
• Other Applications
• 6.4. Global Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Labs
• Clinics
• Hospitals
• Research Centers
• Other End-Users
• 6.5. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Safety Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Toxicity Biomarkers
• Adverse Event Biomarkers
• 6.6. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Efficacy Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacodynamic Biomarkers
• Response Biomarkers
• 6.7. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Validation Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Predictive Biomarkers
• Prognostic Biomarkers
• 6.8. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Biomarkers
• Biomarkers For Disease Progression

7. Central Nervous System Biomarkers Market Regional And Country Analysis

• 7.1. Global Central Nervous System Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Central Nervous System Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Central Nervous System Biomarkers Market

• 8.1. Asia-Pacific Central Nervous System Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Central Nervous System Biomarkers Market

• 9.1. China Central Nervous System Biomarkers Market Overview
• 9.2. China Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Central Nervous System Biomarkers Market

• 10.1. India Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Central Nervous System Biomarkers Market

• 11.1. Japan Central Nervous System Biomarkers Market Overview
• 11.2. Japan Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Central Nervous System Biomarkers Market

• 12.1. Australia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Central Nervous System Biomarkers Market

• 13.1. Indonesia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Central Nervous System Biomarkers Market

• 14.1. South Korea Central Nervous System Biomarkers Market Overview
• 14.2. South Korea Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Central Nervous System Biomarkers Market

• 15.1. Western Europe Central Nervous System Biomarkers Market Overview
• 15.2. Western Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Central Nervous System Biomarkers Market

• 16.1. UK Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Central Nervous System Biomarkers Market

• 17.1. Germany Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Central Nervous System Biomarkers Market

• 18.1. France Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Central Nervous System Biomarkers Market

• 19.1. Italy Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Central Nervous System Biomarkers Market

• 20.1. Spain Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Central Nervous System Biomarkers Market

• 21.1. Eastern Europe Central Nervous System Biomarkers Market Overview
• 21.2. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Central Nervous System Biomarkers Market

• 22.1. Russia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Central Nervous System Biomarkers Market

• 23.1. North America Central Nervous System Biomarkers Market Overview
• 23.2. North America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Central Nervous System Biomarkers Market

• 24.1. USA Central Nervous System Biomarkers Market Overview
• 24.2. USA Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Central Nervous System Biomarkers Market

• 25.1. Canada Central Nervous System Biomarkers Market Overview
• 25.2. Canada Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Central Nervous System Biomarkers Market

• 26.1. South America Central Nervous System Biomarkers Market Overview
• 26.2. South America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Central Nervous System Biomarkers Market

• 27.1. Brazil Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Central Nervous System Biomarkers Market

• 28.1. Middle East Central Nervous System Biomarkers Market Overview
• 28.2. Middle East Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Central Nervous System Biomarkers Market

• 29.1. Africa Central Nervous System Biomarkers Market Overview
• 29.2. Africa Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Central Nervous System Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Central Nervous System Biomarkers Market Competitive Landscape
• 30.2. Central Nervous System Biomarkers Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Central Nervous System Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Eurofins Scientific
• 31.3. Charles River Laboratories International Inc.
• 31.4. PerkinElmer Inc.
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. QIAGEN N.V.
• 31.7. Axon Neuroscience SE
• 31.8. Alector Inc.
• 31.9. Oryzon Genomics S.A.
• 31.10. Abastar Mdx Inc.
• 31.11. Banyan Biomarkers Inc.
• 31.12. Avacta Group PLC
• 31.13. Geno Technology Inc.
• 31.14. Anavex Life Sciences Corp.
• 31.15. Alseres Pharmaceuticals Inc.

32. Global Central Nervous System Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System Biomarkers Market

34. Recent Developments In The Central Nervous System Biomarkers Market

35. Central Nervous System Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Central Nervous System Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Central Nervous System Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Central Nervous System Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer